“Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies” (Shering-Plough Release)
“Abbott Completes Acquisition of Evalve, Inc.” (Press release from Abbott)
“BRIEF-GlaxoSmithKline, Valeant file Retigabine with FDA” (Reuters)
“Excitement grows on more positive data for HGS/GSK lupus drug” (Pharma Times)
“US House health bill “could cost pharma $150 billion” (PharmaTimes)
“GlaxoSmithKline, Valeant File Retigabine New Drug Application” (Dow Jones Newswires)
“Soleil Securities Reiterates a ‘Buy’ on Pfizer (PFE); Recent Pullback Provides Opportunity Ahead of Catalysts” (StreetInsider.com)
“Schering-Plough reports data on hepatitis C drug” (Associated Press)
“Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases” (Press release by Quark Pharmaceuticals)
“Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development” (Business Wire)
SUBSCRIBE